Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Review

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms

A. Kapoor Bipinesh Sansar Anuj Gupta B. Mishra Archi Rungta Ankita Pal Shreya Srivastava M. Shah N. Menon Trupti Pai O. Shetty P. Chandrani A. Choughule V. Noronha K. Prabhash
Aug 2026 · Medical Oncology · Vol 43 · 0 citations · 62 references
Medicine

TL;DR

KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.

DOI PubMed Semantic Scholar
View source

Similar papers

Review Sep 2026

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.

T. Sagawa, Masahiro Hirakawa, H. Nagashima et al. · 1 citation
Open access Aug 2026

Targeting KRAS in Cancer: Advances in Precision Oncology and Drug Development

These breakthroughs have validated direct KRAS inhibition as an effective therapeutic strategy, however, durable clinical responses remain limited by intrinsic and acquired resistance, pathway reactivation, tumour heterogeneity, and the lack of effective therapies for non-G12C KRAS mutations.

Pasham Uma, Dandotikar Neha, R. Manisha et al. · 0 citations
Review Open access Jul 2026

KRAS G12C-Targeted Therapy Strategy for Lung Cancer: Mechanism, Clinical Practice and Challenges

This review systematically summarizes the molecular mechanisms driving KRAS G12C‑mutant lung cancer, clinical applications of targeted drugs, resistance and heterogeneity challenges, and progress in combination therapy, providing a reference for clinical decision-making and further research in this field.

Xizhi Zha · 0 citations
Review Open access Jul 2026

Recent advances in EGFR-targeted therapies for non-small cell lung cancer

This review discusses recent advances in EGFR-targeted therapies within the molecular landscape of classical and uncommon EGFR mutations, focusing on frontline intensification strategies in metastatic disease—specifically TKI combinations with chemotherapy or bispecific antibodies or bispecific antibodies—and emerging...

L. Lucente, Lucrezia Barcellini, Beatrice Ramella Pollone et al. · 0 citations
Review Aug 2026

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions

The biologic rationale, current clinical evidence, practical guideline-based positioning, practical guideline-based positioning, toxicity management considerations, resistance mechanisms, and emerging therapeutic strategies for KRAS G12C-mutated mCRC are summarized.

T. Sagawa, H. Nagashima, K. Fujikawa · 0 citations
Review Open access Aug 2026

From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies.

This review synthesizes current knowledge on KRAS resistance mechanisms and highlights emerging therapeutic strategies, including rational combination approaches, enhanced RAS pathway suppression, targeted protein degradation, and KRAS-directed immunotherapies.

Rawan Salih, F. Sirajudeen, Mohamed Rahmani · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.